サンプル依頼リスト カート
  • English
  • Korean
表紙：ハンチントン病の世界市場-2023年～2030年
市場調査レポート
商品コード
1347974

ハンチントン病の世界市場-2023年～2030年

Global Huntington's Disease Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ハンチントン病の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

ハンチントン病は、中枢神経系（CNS）の神経細胞が変性する遺伝性疾患です。この疾患はヒトの機能的能力に広範な影響を及ぼし、通常、運動障害と思考障害が生じます。ほとんどのハンチントン病患者は30～40歳で徴候や症状が出現します。

20歳以前に発症した場合は若年性ハンチントン病と呼ばれます。男女ともにこの病気にかかりやすいです。この疾患は遺伝性の神経変性疾患であり、運動症状、認知症状、精神症状を伴います。

ダイナミクス

パイプライン医薬品の増加

ハンチントン病治療薬の世界市場の成長を支えているのは、高い患者コンプライアンスや安全性の向上といった特性を持つ、豊富なパイプラインです。例えば、米国ハンチントン病学会によると、UniQure社は、ハンチンチン変異タンパク質を沈黙させるように設計された遺伝子治療薬AMT-130を開発しています。PTCセラピューティクス社もPTC518という経口スプライスモジュレーターを開発し、ハンチンチンのレベルを下げています。

セージ・セラピューティクス社はNMDA受容体拮抗薬Sage-718の開発に取り組んでおり、ハンチントン病患者を対象とした初期の安全性試験を完了しました。

アネクソン・バイオサイエンシズ社は、HD脳内のニューロン（シナプス）間の結合を維持することを目的とした点滴静注用抗体ANX-005を開発中です。SRX246は、HDの初期段階における不安や攻撃性の症状を治療する治験薬で、アゼバン・ファーマシューティカルズが発明しました。これらの医薬品は現在パイプラインにあり、広範囲に試験され、承認後に市場に投入されます。

さらに、高度な疾患治療に対する需要の増加、慢性疾患に対する意識の高まり、新薬の発見などは、今後の市場を牽引するいくつかの要因です。

臨床試験の終了

現在、コレア（舞踏運動）の治療薬として承認されているのは、テトラベナジンとドイテトラベナジンの2剤のみです。それ以外には、複数の企業が開発に取り組んだもの、現在に至るまで承認された医薬品はありません。例えば、ノバルティスは当初、脊髄性筋萎縮症という小児疾患の治療薬として経口薬のブラナプラムを開発しました。この薬は、RNAスプライシングとして知られるプロセスの遺伝子レシピを阻害することによって、ハンチントンタンパク質を低下させることも発見されました。残念ながら、成人のHD患者を対象とした第2相臨床試験は、ブラナプラムが予期せぬ神経損傷を引き起こしたため、安全上の理由から2022年に中止されました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究開発の増加
      • パイプライン医薬品の増加
    • 抑制要因
      • 医薬品の承認不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMIの見解

第6章 COVID-19分析

第7章 薬剤クラス別

  • テトラベナジン
  • ドイテトラベナジン
  • 抗精神病薬
    • クロナゼパム（クロノピン）
    • ハロペリドール
    • クロザピン
    • その他
  • 向精神薬
    • フルオキセチン（プロザック）
    • セルトラリン（ゾロフト）
    • シタロプラム（セレクサ）
    • その他
  • 抗ドーパミン薬
    • メトクロプラミド
    • ドロペリドール
    • ハロペリドール
    • クロルプロマジン
    • その他
  • 抗うつ薬
    • シタロプラム
    • エスシタロプラム
    • セルトラリン
    • その他
  • その他

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Teva Pharmaceutical Industries Ltd.
    • 企業概要
    • 診断ポートフォリオと概要
    • 財務概要
    • 主な動向
  • Apotex Corporation
  • Pfizer, Inc.
  • Rosemont Pharma
  • Agnito Pharma
  • Merck & Co, Inc.
  • Eli Lilly and Company
  • Ralington Pharma
  • Par Pharmaceutical
  • Accord Healthcare

第12章 付録

目次
Product Code: PH2221

Overview

Huntington's disease is an inherited disease that causes the degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on the functional abilities of humans and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in the age of 30 to 40.

When the disease begins before age 20, the condition is known as juvenile Huntington's disease. Both men and women are susceptible to this disease. It is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms.

Dynamics

Increasing Pipeline Drugs

Extensive pipeline drugs with properties such as high patient compliance and improved safety also support the growth of the global Huntington's disease therapeutics market. For instance, according to Huntington's Disease Society of America, UniQure is developing AMT-130, a genetic drug designed to silence the huntingtin mutant protein. PTC Therapeutics has also developed an oral splice modulator called PTC518, which reduces huntingtin levels.

Sage Therapeutics is working on Sage-718, an NMDA receptor antagonist that completed an early safety trial in individuals with Huntington's disease.

Annexon Biosciences is developing ANX-005, an antibody given by IV that aims to help preserve the connections between neurons (synapses) in the HD brain. SRX246, an investigational drug to treat symptoms of anxiety and aggression in the early stages of HD, was invented by Azevan Pharmaceuticals. These Drugs are currently in the pipeline, tested extensively, and later released into the market after approval.

Furthermore, the rise in demand for advanced disease treatment, increasing awareness about chronic diseases, new drug discoveries are few factors that drive the market in the forthcoming period.

Termination of Clinical Trials

Currently, only two drugs were approved, Tetrabenazine and deutetrabenazine, for treating chorea. Other than these, there are no approved drugs until now, although several companies worked on the development. For instance, Novartis initially developed Branaplam, an oral drug to treat a childhood disorder called spinal muscular atrophy. It was also found to lower huntington protein by interfering with the genetic recipe in a process known as RNA splicing. Unfortunately, a Phase 2 trial in adults with HD was halted in 2022 for safety reasons after branaplam unexpectedly caused nerve damage.

Segment Analysis

The global Huntington's disease market is segmented based on drug class, distribution channel, and region.

Xenazine (tetrabenazine) and Austedo (deutetrabenazine) are two antidopaminergic medications approved by the U. S. Food and Drug Administration (FDA) to treat symptoms of chorea in Huntington's disease. They work by blocking VMAT proteins and dopamine receptors. Austedo's chemical structure is similar to Xenazine, but it is more stable.

According to an article published in Bionews,Inc. in January 2022, the proportion of patients with an adherence rate of AUSTEDO (Deutrabenazine) refill is higher i.e., 78% compared to Xenazine (tetrabenazine) i.e., 69% was observed in a group of patient population.

Additionally, On October 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. released the results from the ARC-HD (Alternatives for Reducing Chorea in Huntington's Disease) trial, an approximately 3-year open-label, single-arm, 2-cohort, multicenter extension study evaluating the safety and tolerability of long-term treatment with AUSTEDO (deutetrabenazine) tablets for chorea associated with Huntington's Disease (HD).

Geographical Analysis

North America is expected to hold the largest segment due to the drug pipeline, the prevalence of Huntington's disease, and increasing clinical trials.

For instance, according to the Journal of Neurology Research 2022 issue, the worldwide prevalence is extensively varied with an equal distribution between men and women. It is estimated in 5-10 cases per 100,000 inhabitants. Annual incidence varies between one and four cases per million inhabitants.

Additionally, in December 2022, Sage Therapeutics, California, United States is conducting phase 3 clinical trial to evaluate the safety and tolerability of SAGE-718 soft gel lipid capsule in participants with Huntington's Disease (HD)

COVID-19 Impact Analysis

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.

The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of disease-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market.

By Drug Class

  • Tetrabenazine
  • Deutetrabenazine
  • Antipsychotic drugs
    • Clonazepam (Klonopin)
    • Haloperidol
    • Clozapine
    • Others
  • Psychotropic medication
    • Fluoxetine (Prozac)
    • Sertraline (Zoloft)
    • Citalopram (Celexa)
    • Others
  • Antidopaminergics
    • Metoclopramide
    • Droperidol
    • Haloperidol
    • Chlorpromazine
  • Antidepressants
    • Citalopram
    • Escitalopram
    • Sertraline
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the Huntington's disease market include: Teva Pharmaceuticals, Apotex Corporation, Pfizer, Rosemont Pharma, Agnito Pharma, Merck & Co, Eli Lilly Company, Ralington Pharma, Par Pharmaceutical, and Accord Healthcare among others.

Key Developments

  • On July 2023, Lupin Inc., based in Somerset, New Jersey, U.S received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Chlorpromazine Hydrochloride Tablets.
  • In Jan 2022, Ionis Pharmaceuticals, Inc. launched the designing of a phase 2 trial by their partner Roche to assess Tominersen in Huntington's disease.

Why Purchase the Report?

  • To visualize the global Huntington's disease market segmentation based on drug class, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Huntington's disease market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global Huntington's disease market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Diagnosis
  • 3.2. Snippet by Drug/Therapy
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research and Development
      • 4.1.1.2. Rising Pipeline Drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Drug Approvals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Tetrabenazine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Deutetrabenazine
  • 7.4. Antipsychotic drugs
      • 7.4.1.1. Clonazepam (Klonopin)
      • 7.4.1.2. Haloperidol
      • 7.4.1.3. Clozapine
      • 7.4.1.4. Others
  • 7.5. Psychotropic medication
      • 7.5.1.1. Fluoxetine (Prozac)
      • 7.5.1.2. Sertraline (Zoloft)
      • 7.5.1.3. Citalopram (Celexa)
      • 7.5.1.4. Others
  • 7.6. Antidopaminergics
      • 7.6.1.1. Metoclopramide
      • 7.6.1.2. Droperidol
      • 7.6.1.3. Haloperidol
      • 7.6.1.4. Chlorpromazine
      • 7.6.1.5. Others
  • 7.7. Antidepressants
      • 7.7.1.1. Citalopram
      • 7.7.1.2. Escitalopram
      • 7.7.1.3. Sertraline
      • 7.7.1.4. Others
  • 7.8. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Teva Pharmaceutical Industries Ltd.
    • 11.1.1. Company Overview
    • 11.1.2. Diagnosis Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Apotex Corporation
  • 11.3. Pfizer, Inc.
  • 11.4. Rosemont Pharma
  • 11.5. Agnito Pharma
  • 11.6. Merck & Co, Inc.
  • 11.7. Eli Lilly and Company
  • 11.8. Ralington Pharma
  • 11.9. Par Pharmaceutical
  • 11.10. Accord Healthcare

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us